Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Adult Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT05479994 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT05479994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05479994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Adult Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Lead sponsor
BeiGene
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 25, 2022
Completion date
August 25, 2027
Enrollment
100 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphoma, refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, relapsed chronic lymphocytic leukemia, small lymphocytic lymphoma